hypeless
Back to the news

Companies

Zydus Lifesciences' Saroglitazar shows higher MASH resolution rates than placebo in phase 2b trial

Reported by: CNBC TV18 ·

WhatsApp

Zydus Lifesciences

Summary

CNBC TV18 reported that Zydus Lifesciences' investigational drug saroglitazar showed higher MASH resolution rates than placebo in a phase 2b trial. Zydus Therapeutics said the drug achieved resolution of steatohepatitis without worsening of fibrosis in 39.1% of patients receiving the 4 mg dose and 32.4% receiving the 2 mg dose. A phase 2b trial is a mid-stage study that tests a drug's dose and effect in patients before larger trials. Steatohepatitis is a liver condition with inflammation and fat build-up, and fibrosis means scarring of the liver. The report gives the share of patients on each dose who met that measure, but not the placebo figure or the number of patients in the trial.

AI summary of what CNBC TV18 reported. AI can make mistakes. Read the full story on CNBC TV18

Sources

Every outlet that reported this story. Each link opens the outlet's own article.

What each outlet wrote

The same news, in each outlet's own headline. Open one to read their full story.

CNBC TV18  · · Tone 0

Zydus Lifesciences' Saroglitazar shows higher MASH resolution rates than placebo in phase 2b trial

Zydus Therapeutics reported that its investigational drug saroglitazar achieved resolution of steatohepatitis without worsening of fibrosis in 39.1% of patients receiving the 4 mg dose and 32.4% receiving 2 mg, compared…

Some headlines quote an analyst. Those views are theirs, not ours.

Earlier coverage

What outlets reported about the same company before this story, newest first.

Ask Hypeless about this story

Ask what it means, what a term in it means, or what other outlets said. Answers use only these outlets' headlines.

Ask Hypeless